Lonza Group Ltd (Lonza) is a contract manufacturing and development solutions company. It offers services including commercial mammalian and microbial manufacturing, clinical development, and manufacturing. It also offers high potential active pharmaceutical ingredients, cell and gene therapy capabilities, advanced intermediates, oral drug product development services, cell-culture modeling, genome editing, endotoxin products, and research media and testing products. Lonza provides solutions for health and well-being, microbial and hygiene control, and composites and material protection. Lonza serves biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; formulators and service companies. The company operates manufacturing and R&D facilities in Asia, Europe, and the Americas. Lonza is headquartered in Basel, Switzerland.
Headquarters
Switzerland
Address
Muenchensteinerstrasse 38, Basel, 4002
Website
www.lonza.com
Telephone
41 61 3168111
No of Employees
16,218
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LONN (SWF)
Revenue (2021)
$5.9B
20%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
238.8%
(2021 vs 2020)
Market Cap*
$40.1B
Net Profit Margin (2021)
XXX
182.3%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| BioResearch Solutions: | Development Technologies | Aldo |
| Stem Cells | GS Xceed Gene Expression System | Biovert |
| Primary Cells and Media | XS Technologies for Microbial Expression | Black Willow Extract |
| XXX | XXX | XXX |
| XXX | XXX | XXX |
| XXX | XXX | XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Corporate Changes/Expansions | In May, the company expanded its Capsugel offering with a titanium dioxide-free (TiO2-free) white hard gelatin capsule, fulfilling the evolving demand of its customers to meet new titanium dioxide-free requirements for foods in the European Union. |
| 2022 | Corporate Changes/Expansions | In May, the company and Kodiak Sciences opened a new bioconjugation facility in Visp, Switzerland. |
| 2022 | Contracts/Agreements | In May, the company and ALSA Ventures collaborated to provide development and manufacturing services for Biotech Firms. |
Competitor Comparison
| Key Parameters | Lonza Group Ltd | Royal DSM NV | Dottikon ES Holding AG | Mabuhay Vinyl Corp | ADC Therapeutics SA |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Netherlands | Switzerland | Philippines | Switzerland |
| City | Basel | Heerlen | Dottikon | Makati | Epalinges |
| No. of Employees | 16,218 | 21,358 | 658 | 153 | 312 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Albert M. Baehny | Chairman | Executive Board | 2018 | - |
| Pierre Alain Ruffieux, Ph.D. | Chief Executive Officer | Senior Management | 2020 | - |
| Philippe Deecke | Chief Financial Officer | Senior Management | 2021 | - |
| Caroline Barth | Chief Human Resources Officer | Senior Management | 2020 | - |
| Christoph Mader | Vice Chairman | Executive Board | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer